Clinical Trial Update: HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 3]

View source ↗

Summary

Phase 3 trial HC-1119 versus enzalutamide for metastatic castration-resistant prostate cancer has been terminated; no results are provided in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• HC-1119
• Xtandi (enzalutamide)

Snippet

Sponsor: Hinova Pharmaceuticals USA, Inc. | Conditions: Prostate Cancer Metastatic, Castration-resistant Prostate Cancer | Phase 3 | Status: TERMINATED